TGen review links gene with the most common liver cancer

April 08, 2019

PHOENIX, Ariz. -- Hepatocellular carcinoma (HCC) is a long medical name for the most common form of liver cancer, a malignancy whose incidence has nearly doubled over the past decade, making it the fastest growing type of cancer in the U.S., and the third-leading cause of cancer-related death worldwide.

In an article published April 5 in the scientific journal Cancers, researchers at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, provide the first summary of the experimental evidence supporting the AKR1B10 enzyme as a promising therapeutic target for HCC, based on a review of more than 50 studies published since this gene was first identified and characterized in 1998.

"While the association between this gene and HCC is well recognized, in this review we see AKR1B10 emerging as not only a therapeutic target for this type of liver cancer, but also having potential use in early diagnosis of this deadly disease," said Dr. Johanna DiStefano, head of the Diabetes and Fibrotic Disease Unit at TGen.

Importantly, AKR1B10 has a seemingly conflicting role in HCC development and progression. This gene's over expression is a clear indicator that a patient might have HCC, and yet the suppression of this gene may also be seen as a way to stop the cancer's progression and spread, said Dr. DiStefano, a Professor at TGen and the paper's senior author.

Like many types of digestive cancers, HCC exhibits few symptoms in its early stages, and is usually not diagnosed until its late stages, when there are fewer options for treatment and the chances of patient survival dim.

In the U.S., the number of liver cancer diagnoses has nearly doubled, from about 22,000 cases in 2009 to an estimated 42,000 cases this year. Men are almost twice as likely to contract this disease than women.

This year, nearly 32,000 patients will die of liver cancer, making it the fifth leading cause of cancer related death in the U.S., following closely on the heels of breast and pancreatic cancers. Worldwide, liver cancer is the third leading cause of cancer related death, according to the review paper: Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma.

HCC is the most common cause of death in patients with cirrhosis of the liver, which is most strongly associated with overconsumption of alcohol, viral infections and nonalcoholic fatty liver disease (NAFLD).

While AKR1B10 has emerged as a potential biomarker for the diagnosis and prognosis of HCC, studies show this enzyme also plays a role in the development and progression of HCC, the paper says. AKR1B10 appears to affect HCC's resistance to currently available chemotherapies, making HCC more difficult to treat. At the same time, the TGen paper shows that higher expression of this gene is paradoxically associated with better long-term outcomes, increased survival rates and lower incidence of metastatic spread to other parts of the body. The aggregate findings suggest that AKR1B10 may be performing different functions at different stages of HCC.

"Identification of biomarkers for various stages of HCC is critical to improving early disease detection and enabling early implementation of chemotherapy and surgical removal of the tumor to prevent the cancer's progression and spread to other organs," said Dr. Bethany Davis, a post-doctoral fellow in Dr. DiStefano's lab and also an author of the paper.

The molecular mechanisms underlying HCC, and the role AKR1B10 plays in this disease, however, continue to remain poorly understood, Dr. DiStefano said.

"Still, our review shows that AKR1B10 might be exploited for early cancer prevention," she said. "And the value of this gene in therapies and clinical management of specific subtypes of HCC clearly warrant further investigation."
-end-
This review study was funded by TGen.

About TGen, an affiliate of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: http://www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: http://www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.

The Translational Genomics Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.